Lilly's Elanco unit buying pet vaccine portfolio IBJ .pdf
Original filename: Lilly's Elanco unit buying pet-vaccine portfolio _ IBJ.pdf
This PDF 1.4 document has been generated by Mozilla/5.0 (Windows NT 6.1; WOW64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/53.0.2785.143 Safari/537.36 / Skia/PDF m53, and has been sent on pdf-archive.com on 11/10/2016 at 16:50, from IP address 50.79.x.x.
The current document download page has been viewed 7965 times.
File size: 97 KB (1 page).
Privacy: public file
Download original PDF file
Lilly's Elanco unit buying petvaccine portfolio for
October 5, 2016
Eli Lilly and Co. announced Wednesday that its Elanco animalhealth unit is buying Germanybased Boehringer
Ingelheim International's U.S. feline, canine and rabies vaccines portfolio, as well as related manufacturing and
R&D, for $885 million.
The deal will buttress Elanco’s presence in the pet segment of animal health, which is enjoying robust growth.
Future Market Insights reported this month that the segment is expected to register a compound annual growth
rate of 4.9 percent globally from 2015 to 2025.
"We understand the unique bond that owners share with pets and are committed to helping those pets live longer,
healthier lives," Jeff Simmons, president of Greenfieldbased Elanco, said in a statement. "With a growing
portfolio addressing both prevention and treatment of disease, Elanco can partner with veterinarians and pet
caregivers to do just that."
The purchase adds vaccines for bordetella, Lyme disease, rabies and parvovirus to Elanco’s U.S. product
portfolio, which includes products for parasiticides, pain and dermatology.
As part of the purchase, Elanco is acquiring a Boehringer Ingelheim factory in Fort Dodge, Iowa, that makes the
acquired products. The facility also is equipped with R&D and testing capabilities, including a veterinary
research center and lab space.
Boehringer Ingelheim’s divestiture of its U.S. vaccines business was required by antitrust regulators scrutinizing
the company’s purchase of Merial, the animal health business of Francebased Sanofi. Boehringer is getting
Merial as part of a $25 billion asset swap with Sanofi that includes overthecounter drugs and consumer health
Lilly has been aggressively bulking up Elanco in recent years, most notably with the $5.4 billion purchase of the
animal health unit of Switzerlandbased Novartis last year. This is Elanco's 10th acquisition since 2007.
In the second quarter of 2016, Elanco reported sales of $860 million, up 2 percent from the same period a year
earlier. Lilly overall had sales in the quarter of $5.4 billion.